Two years ago, I made a decision that most of my colleagues would question and none of my patients would hear me endorse: I started injecting low-dose tirzepatide — not for weight loss, not for diabetes, but for something far less conventional. I did it because the evidence, while incomplete, pointed toward a drug whose benefits might extend well beyond the indications printed on the label. And I did it because I'm the kind of physician who believes that if you're going to speak with conviction about a medication, you should understand what it actually feels like to take it.

What started as an exercise in empathy — a doctor trying to develop a shared vocabulary with his patients — became something I didn't expect. It became personal.

The clinical data on GLP-1 receptor agonists over the past several years has been nothing short of extraordinary — and not just for the metabolic outcomes everyone talks about. Across the drug class, evidence has accumulated suggesting potential benefits in cardiovascular risk reduction, musculoskeletal health, systemic inflammation, cancer risk, and even neurocognitive protection. Some of this is robust. Some of it is still emerging. But the trajectory of the evidence — particularly the predictive success of early data being validated by larger trials — gave me enough confidence to make a calculated bet on myself.

My protocol has been conservative by any standard: a few milligrams of tirzepatide, injected weekly to every two or three weeks, depending on the period. I've used branded formulations exclusively for two years. This is a fraction of the doses used in the landmark obesity and diabetes trials, and that's intentional. I wasn't chasing aggressive weight loss. I was pursuing something more diffuse — a multi-organ hedge against long-term risk from a drug that I believed had already demonstrated an unusually favorable safety profile in someone like me: lower risk for the traditional indications.

On some level, this is performance-based. That word carries uncomfortable connotations in medicine, but I think it's the most honest framing available. My pursuit is less about treating a verified condition and more about optimizing how I function — physically and cognitively — within the margins that this class of drug appears to offer.

Here's the part that surprised me most, and it happened almost immediately.

Even at the lowest doses, I noticed a reduction in what I can only describe as cognitive noise. Not the kind of noise you'd associate with clinical anxiety or attention deficits — something subtler. The subcortical hum of dopamine-mediated impulses that push you toward compulsive behaviors without your conscious permission. The pull toward stress eating after a long shift. The low-grade mental negotiation with distraction that eats into deep work without announcing itself.

That quieted.

If you've read my previous work on appetite regulation and the neuroscience of food noise, this will sound familiar. Hunger and satiety aren't generated in the cortical regions associated with conscious decision-making — they arise subcortically, in the hypothalamus and area postrema, regions that operate beneath the threshold of deliberate thought. What GLP-1 receptor agonists appear to do, at least experientially, is reduce the volume on those signals. Not silence them. Reduce them enough that the conscious mind — the part of you that actually wants to focus on the patient in front of you, the paper you're writing, the conversation you're in — gets the space it needs.

I've started calling this cognitive deloading, and I think it's among the most underappreciated effects of this drug class. It isn't just that I eat less or eat differently. It's that the cognitive overhead associated with managing subcortical impulses — the constant, low-level negotiation with cravings, with the pull toward short-term reward — has been reduced in a way that frees up meaningful mental resources. I'm more focused on higher-value tasks throughout the day. I'm more resilient when dealing with everyday stress because I'm simply less likely to default to compulsive coping mechanisms.

This is not a productivity hack. I don't frame it that way because that trivializes the pharmacology. But it would be dishonest to pretend the effect isn't real and isn't significant.

At the doses I've used, side effects have been minimal — and that's a meaningful part of the appeal. The GI burden that dominates patient conversations at therapeutic doses for weight management has been largely absent for me. I won't pretend this is universally transferable; individual responses vary enormously with these drugs. But for my particular physiology, at my particular dose range, the tolerability has been remarkably favorable.

This matters because it changes the risk-benefit calculus. When side effects are negligible and the potential upside spans multiple organ systems over a long time horizon, the math starts to look different than when you're counseling a patient through nausea at 10 or 15 milligrams.

I'd be lying if I said I didn't wrestle with this. The most uncomfortable thought wasn't about pharmacology — it was about access. Am I, a physician using this drug off-label for non-traditional purposes, directly preventing someone else from getting the medication they need for a medically urgent indication?

I sat with that question for a long time.

And where I've landed — imperfectly, and with full acknowledgment that reasonable people will disagree — is that the system bears more responsibility for this problem than any individual user. The pricing of GLP-1 receptor agonists has created a landscape where access is determined not by clinical need but by insurance formularies, prior authorization bureaucracies, and out-of-pocket costs that place these drugs out of reach for the vast majority of people who would benefit most. The shortage of these medications is real, and so is the suffering it causes. But the root of that shortage is a pricing and distribution failure, not an individual prescribing decision.

I don't find this fully satisfying as an ethical resolution. But I do find it more honest than pretending that my abstention would meaningfully change the access landscape for the millions of people who can't afford these drugs, regardless.

I started this two years ago because I thought it would make me a better clinician — that having firsthand experience with the medication my patients were taking would sharpen my empathy and improve my counseling. That part proved true. There's a quality of understanding you simply can't get from reading trial data alone.

But what I didn't anticipate was how much this experience would deepen my conviction about the broader thesis of this newsletter: that the biology of weight regulation, appetite, and metabolic health operates largely beyond the reach of conscious willpower, and that pharmacological tools capable of intervening at that level deserve a far more expansive conversation than the one we're currently having.

The fact that a low-dose GLP-1 receptor agonist can reduce compulsive behavior, improve sustained attention, and dampen the stress-reward loop — in someone who isn't clinically obese, who doesn't have diabetes — tells us something important about what these drugs are actually doing. They aren't just weight loss drugs. They're acting on the fundamental neurocircuitry that governs how we allocate cognitive and behavioral resources in an environment that relentlessly exploits our subcortical wiring.

I don't think pharmaceutical companies will formally pursue many of these indications. The financial incentives don't align with the more speculative applications. But I'm cautiously optimistic that validation will come over time — through off-label observation, through adjacent trials, and through the accumulating experience of clinicians and patients who are paying close attention to what these drugs do beyond the label.

I remain cautiously optimistic. Cautiously — because much of the multi-organ data I've anchored my decision to is still early, and intellectual honesty requires sitting with that uncertainty. Optimistic — because two years of personal experience, layered on top of a rapidly growing evidence base, have given me more reason to continue than to stop.

I'm not telling you to do what I've done. I'm telling you what I've done, what I've observed, and what I think it means for the future of this drug class — because you deserve substance over noise, even when the substance is uncomfortably personal.